[DOI] [Google Scholar] 21.Lee S., Chen T.T., Barber C.L., Jordan M.C., Murdock J., Desai S., Ferrara N., Nagy A., Roos K.P., Iruela-Arispe M.L
After treatment with CoCl, BPC157-treated HUVECs failed to form tube-like structures (Supplementary Figure S3B), which is consistent with our analysis that the redox state is a key determinant of BACH1s functional direction
Once the BPC-157 is in a solution, it's no longer in a protected, dormant state
Technical Specifications Compound: BPC-157 (Synthetic Pentadecapeptide) Format: Lyophilized peptide powder Strength: 10 mg per vial Purity: 9899% (COA included) Appearance: White lyophilized powder Category: Research peptide reagent Intended Use This product is intended strictly for: Laboratory experimentation In-vitro scientific research Biochemical and molecular studies Non-human preclinical model development Institutional or academic research programs Not intended for: Human or animal consumption Injection, ingestion, inhalation, or topical use Medical, therapeutic, diagnostic, or cosmetic purposes This compound is not approved by Health Canada, FDA, or any regulatory authority for clinical use
Ordered two more formats on the strength of this first order. We run tight quality gates on every reagent that comes into our lab
